Rossari Biotech Past Earnings Performance
Past criteria checks 5/6
Rossari Biotech has been growing earnings at an average annual rate of 16%, while the Chemicals industry saw earnings growing at 14.6% annually. Revenues have been growing at an average rate of 13.4% per year. Rossari Biotech's return on equity is 12.4%, and it has net margins of 7.2%.
Key information
16.0%
Earnings growth rate
13.5%
EPS growth rate
| Chemicals Industry Growth | 17.7% |
| Revenue growth rate | 13.4% |
| Return on equity | 12.4% |
| Net Margin | 7.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Rossari Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19,245 | 1,388 | 1,189 | 0 |
| 30 Jun 24 | 19,096 | 1,364 | 1,072 | 0 |
| 31 Mar 24 | 18,306 | 1,307 | 1,098 | 0 |
| 31 Dec 23 | 17,643 | 1,255 | 1,084 | 0 |
| 30 Sep 23 | 16,898 | 1,168 | 1,065 | 0 |
| 30 Jun 23 | 16,318 | 1,078 | 1,031 | 0 |
| 31 Mar 23 | 16,559 | 1,073 | 1,039 | 0 |
| 31 Dec 22 | 16,883 | 1,027 | 997 | 0 |
| 30 Sep 22 | 17,275 | 995 | 957 | 0 |
| 30 Jun 22 | 16,866 | 1,018 | 855 | 0 |
| 31 Mar 22 | 14,830 | 977 | 735 | 0 |
| 31 Dec 21 | 12,623 | 957 | 610 | 0 |
| 30 Sep 21 | 10,438 | 948 | 516 | 0 |
| 30 Jun 21 | 8,310 | 892 | 462 | 0 |
| 31 Mar 21 | 7,093 | 802 | 456 | 0 |
| 31 Dec 20 | 6,507 | 729 | 423 | 0 |
| 30 Sep 20 | 6,031 | 695 | 415 | 0 |
| 30 Jun 20 | 5,818 | 666 | 389 | 0 |
| 31 Mar 20 | 6,001 | 653 | 396 | 0 |
| 31 Mar 19 | 5,162 | 457 | 301 | 0 |
| 31 Mar 18 | 2,922 | 254 | 213 | 0 |
| 31 Mar 17 | 2,350 | 143 | 195 | 0 |
Quality Earnings: 543213 has high quality earnings.
Growing Profit Margin: 543213's current net profit margins (7.2%) are higher than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543213's earnings have grown by 16% per year over the past 5 years.
Accelerating Growth: 543213's earnings growth over the past year (18.8%) exceeds its 5-year average (16% per year).
Earnings vs Industry: 543213 earnings growth over the past year (18.8%) exceeded the Chemicals industry 8%.
Return on Equity
High ROE: 543213's Return on Equity (12.4%) is considered low.